טוען...
Inhibitors of Cyclin-Dependent Kinases as Cancer Therapeutics
Over the past two decades there has been a great deal of interest in the development of inhibitors of the Cyclin-dependent kinases (CDKs). This attention initially stemmed from observations that different CDK isoforms have key roles in cancer cell proliferation through loss of regulation of the cell...
שמור ב:
| הוצא לאור ב: | Pharmacol Ther |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6141011/ https://ncbi.nlm.nih.gov/pubmed/28174091 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pharmthera.2017.02.008 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|